Cargando…
Biosimilars: Company Strategies to Capture Value from the Biologics Market
Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to...
Autores principales: | Calo-Fernández, Bruno, Martínez-Hurtado, Juan Leonardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816668/ https://www.ncbi.nlm.nih.gov/pubmed/24281342 http://dx.doi.org/10.3390/ph5121393 |
Ejemplares similares
-
The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond
por: Chang, Lin-Chau
Publicado: (2019) -
Expected Impact of Biosimilars on the Pharmaceutical Companies
por: Golshani, Shiva, et al.
Publicado: (2021) -
Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022) -
The Handbook of Marketing Strategy for Life Science Companies
por: Denault, Jean-Francois
Publicado: (2018) -
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
por: Luukkanen, Saana V., et al.
Publicado: (2022)